LONDON (Reuters) - The existing drugs aren’t working, so big pharmaceutical companies are set to step up the hunt for assets to buy in promising fields like biotechnology, as well as non-prescription areas of healthcare.
LONDON (Reuters) - The existing drugs aren’t working, so big pharmaceutical companies are set to step up the hunt for assets to buy in promising fields like biotechnology, as well as non-prescription areas of healthcare.
